Characterizing Cannabidiol Use in a Breast Cancer Population

Area of Science:

• Oncology
• Pharmacology
• Cannabinoid Science

Background:

• Cannabidiol (CBD), a Cannabis sativa phytocannabinoid, shows potential therapeutic value.
• Limited data exists on CBD use specifically within the breast cancer (BC) patient population.
• This study investigates CBD usage patterns, benefits, and limitations in BC patients.

Purpose of the Study:

• To characterize current and former CBD use among breast cancer patients.
• To identify patient-reported benefits, barriers, and limitations associated with CBD use.
• To inform clinical practice regarding physician guidance on CBD for symptom management.

Main Methods:

• An anonymous online survey was distributed to breast cancer patients at the University of Michigan Rogel Cancer Center.
• Survey questions were adapted from a validated questionnaire used in chronic pain populations.
• Data was collected from September 2020 to February 2024 from 141 evaluable surveys.

Main Results:

• 48.2% of surveyed patients (68/141) reported current or prior CBD use.
• Primary reasons for use included pain (75.6%), anxiety (61.0%), and insomnia (58.5%).
• Median self-reported improvement was highest for insomnia, followed by pain; ineffectiveness was the main reason for discontinuation (46.2%).

Conclusions:

• A significant proportion of breast cancer patients utilize CBD, reporting symptom improvements.
• Physician guidance is crucial for navigating patient concerns regarding CBD use.
• Further research is warranted to identify specific patient-reported symptoms most responsive to CBD therapy.